ClinicalTrials.gg
Not yet recruitingNCT06999317CARAMEL RSUpdated Jan 15, 2026

CARAMEL: Retrospective Study for Personalized Risk Assessment of Cardiovascular Disease in Menopausal and Perimenopausal Women Using Real World Data

An observational study in Cardiovascular Risk Factors, Menopausal Women and Perimenopausal Women, sponsored by Hospital Universitario Virgen Macarena. Not yet recruiting. Open to female participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-01-15.

Sponsored by Hospital Universitario Virgen Macarena · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1,500,000
Ages
40 Years to 60 Years
Sex
Female
01

Study summary

This retrospective observational study, part of the EU-funded CARAMEL project, aims to develop and validate personalized cardiovascular disease (CVD) risk assessment models specifically designed for menopausal and perimenopausal women (ages 40-60). The study leverages Real World Data (RWD) collected from multiple international clinical partners, including electronic health records (EHR), diagnostic imaging data, and signal data.

The main objective is to improve the prediction of CVD precursors such as hypertension and dyslipidemia, as well as mid- and long-term risk of CVD events, through advanced artificial intelligence (AI) models. These models will be trained on multimodal data to capture complex, individualized risk trajectories that current risk calculators fail to address, particularly in women. Special focus is placed on under-researched, women-specific risk factors and their interactions with traditional predictors.

The study includes several research objectives: (1) predicting the onset of hypertension and dyslipidemia using EHR data; (2) modeling the long-term risk of fatal and non-fatal cardiovascular events and disease trajectories; (3) identifying novel imaging biomarkers from routine screening tests such as mammography, DXA, ultrasound, and cardiac MRI; (4) developing multimodal prediction models combining imaging and clinical data; (5) creating automated AI tools for imaging biomarker extraction; and (6) using signal data from cardiac devices to predict disease progression and events.

The study population consists of middle-aged women with retrospective data available across different health systems. The expected outcome is a validated set of stratified, personalized CVD risk models that can support targeted prevention strategies and enable more equitable, sex-specific care. This will contribute to reducing the burden of CVD in women and addressing critical gaps in early detection, clinical decision-making, and health policy.

This project has received funding from the European Union's Horizon Europe Research and Innovation Programme under Grant Agreement No 101156210.

02

Conditions studied

  • Cardiovascular Risk Factors
  • Menopausal Women
  • Perimenopausal Women
  • Real World Data

Keywords

  • Cardiovascular Disease
  • Cardiovascular risk factors
  • Menopausal women
  • Perimenopausal women
  • real world data
  • personalised prevention
  • computational modelling
  • women-specific risks
03

In context

Cardiovascular Diseases

5,376 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's planned enrollment of 1,500,000 is above the median of 534 across 1,577 observational studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Hospital Universitario Virgen Macarena is the lead sponsor of 18 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 60 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants are identified retrospectively from electronic health records, imaging archives, and device registries across multiple healthcare systems and countries

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Self-identified as female in the electronic health record (EHR). Age between 40 and 60 years at the time of data collection/index date. Availability of at least 5-6 years of retrospective data in the EHR, depending on the research objective.

At least one healthcare encounter (visit, imaging, lab test, diagnosis, etc.) within the defined age range.

For imaging substudies (e.g., RO3-RO5): availability of at least one relevant imaging test (e.g., DXA, digital mammography, cMRI, CCTA, US) during the age range.

For signal-based analysis (RO6): presence of monitoring data from implanted devices and at least 2 years of follow-up.

Exclusion criteria

Exclusion Criteria:

Prior diagnosis of cardiovascular disease before the observation window (only applicable to specific ROs, e.g., RO2, RO4).

Insufficient data quality or missing key variables needed for modeling (e.g., absence of blood pressure or lipid profile).

Patients with incomplete or inconsistent records (e.g., duplicate IDs, mismatched time frames).

For signal-based RO6: hospitalizations or diagnoses unrelated to cardiovascular health that may bias AI model training.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1,500,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • ASCIRES IMAGE DATABASE

    Digital imaging biobank 10y long from several manufact 1,000 cMRI; 500 cardiac CT; 500 coronary artery calcification; 1,000 DXA From women 40- 60y urers / modalities

  • Basque Health Service Database

    Longitudinal EHR data up to 15y including diagnosis, procedures, prescriptions, lab tests, visits, imaging, etc. \~128,00 women 40-60 14,880 DM, 3,124 DXA, 332 carotid US

  • Clalit Primary Prevention Database

    Manually curated DB of structured EHR data \~750,000 middleaged women

  • Irish Implant Devices Registry

    Irish Implant Devices Registry (REG) (HRI) 15y of data for implant procedures and follow-ups (pacemakers, ICD's, loop recorders) \~85,000 implant (pacemaker) proced ures \~700,000 follow-up w. indications \& diagnosis

  • Keralty Colombia Database

    EHR data from primary/specialised care centres. Longitudinal EHR data up to 5-10y Including diagnosis, procedures, prescriptions, lab tests, visits, etc. \~85,593 women 40-60y \~25,000 women with CVD problems

  • Andalusian Health Population Database & Macarena University Hospital EHR

    Longitudinal EHR data up to 15y including diagnosis, clinical procedures, prescriptions, lab tests, visits, etc. The hospital Dataset is OMOP CMD mapped \~700,000 middleaged women

  • Lithuanian High Cardiovascular Risk (LitHiR) primary prevention programme database

    EHR data from primary cardiovascular prevention programme in VULSK (1 centre). Data including demographics, risk factors, lab tests (including lipid profile, renal function, etc.), arterial markers (pulse wave velocity analysis data; CardioAngle Vascular Index data; carotid artery intimamedia thickness data). Some patients have 5-10y longitudinal data with outcomes. \~6000 women 40-65y with high - very high cardiovascular risk, but without overt CVD;

  • National and Kapodistrian University of Athens Database - Aretaieion Hospital

    EHR data from Menopause clinic of Aretaieion university hospital including blood tests, medication, prescriptions, visits \~4000 middle aged women

  • CoroPrevention - Tampere University (TAU)

    Pan-European (25 sites) contemporary prospective CVD prevention cohort from ongoing HEU project it includes clinical data, 3-year CV event data, lifestyle, RFs. Standard + CVD biomarkers (CERT2, hsTNI, NTproBNP, Cystatin C…) N=\~3,000 women (subsample of whole cohort)

  • AKRIBEA - Cooperative Research Centre for Biosciences Association (CIC)

    Non-oriented 7y follow-up cohort from Basque Country Region. Urine+serum biomarkers and metabolome; serum lipoproteins by NMR; demographics \& RFs N=\~ 2,500 women (40 to 60 y)

  • MENO - Cooperative Research Centre for Biosciences Association (CIC)

    Pre- and post-menopausal women cohort from Basque Country Region. Urine+serum biomarkers and metabolome; serum lipoproteins by NMR; demographics \& RFs N =\~ 1,700 women

  • UK Biobank - UK Biobank

    Largest geno-phenotype-rich population-based study in the world (500K), includes multi-modal imaging data (60K) and eye and vision (67K), biomarkers, demographic data, lifestyle (100K with wearables) and health outcomes. Middle-aged women among: * 500K baseline * 60K imaging study * 67K retina \& OCT

  • Qatar Biobank

    Population-based with annotated data, biological samples, tests and imaging for 60K participants. It includes Demographics data, lifestyle, biomarkers, weight \& body fat, hip\&waist, BP, ECG, carotid US, full-body MRI, retinography, DXA Middle-aged women among \~60K total participants

  • International Agency for Research on Cancer (IARC) / EPIC-Europa

    Long-term European population-based cohort (520K participants across 10 countries). Includes clinical data, anthropometric measurements, demographic, lifestyle, dietary habits, and socioeconomic data, reproductive history, and biological samples such as serum, plasma and DNA for biochemical data and genotyping data N = \~367k women between 35 to 65 years old (subsample of whole cohort) \~65k CVD cases across the full cohort

  • ILERVAS -Institute for Research in Biomedicine IRB Lleida

    Interventional longitudinal study that includes detailed assessments of subclinical atheromatosis in 12 vascular territories using ultrasound, along with clinical, anthropometric, lifestyle, dietary, and biochemical data. N = \~4165 women (50 to 70y) (subsample of whole cohort)

06

What researchers measure

Primary outcomes

  1. Occurrence and Predicted Risk of Cardiovascular Disease (CVD) Events (fatal and non-fatal)

    The study will retrospectively evaluate the occurrence of cardiovascular disease (CVD) events and develop predictive models to estimate individual risk profiles for such events. CVD events include both fatal and non-fatal occurrences such as myocardial infarction, stroke, heart failure, arrhythmias, and atherosclerotic disease. Events will be identified using structured electronic health records (EHR) and coded using ICD-10 classifications. Risk will be modeled using multimodal data sources (EHR, imaging, and signals) to predict short- and long-term outcomes, stratified by individual characteristics. The outcome integrates: Event-based measures: Time to first fatal or non-fatal CVD event. Risk-based measures: Individual predicted probabilities of experiencing a CVD event or precursor condition (e.g., hypertension, dyslipidemia) over different time frames.

    Time frame: up to 10 years

Secondary outcomes

  1. RO1. Personalized risk prediction of CVD precursors

    First observation of HT or DY registered in the EHR, registered as a diagnostic code, or as a laboratory result or test. These include: * Diagnosis of HT registered in the EHR with either of the following ICD10 codes: * I10 Essential (primary) hypertension * I11.0 Hypertensive heart disease with heart failure * I11.9 Hypertensive heart disease without heart failure * I12.0 Hypertensive chronic kidney disease with stage 5 chronic kidney disease or end stage renal disease * I13.0 Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease * I13.1 Hypertensive heart and chronic kidney disease without heart failure * I13.2 Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease * Diagnosis of DY registered in the EHR with either of the following ICD10 codes: * E78.1 Pure hyperglyceridemia * E78.2 Mixed hyperlipidemia

    Time frame: up to 8 years

  2. RO2. Personalized Risk Prediction of CVD Events and CVD trajectories

    The occurrence of CVD events, which will be classified in fatal (if they are registered as the cause of death) or not fatal (if they are not registered as cause of death). * Fatal CVD events include the following ICD codes registered in the EHR: * I10-16 Hypertensive disease * I20-25 Ischemic heart disease * I46-52 Arrhythmias and heart failure, excluding I51.4 (Myocarditis unspecified) * I60-69 Cerebrovascular diseases * I70-73 Atherosclerosis/AAA * Not fatal CVD events include only the following ICD codes: * I21-I23 Not fatal myocardial infarction * I60-69 Not-fatal stroke

    Time frame: Up to 16 years

  3. RO3. Novel Imaging Biomarkers and Patterns for CVD Risk Assessment

    Evaluates the predictive performance of multimodal models combining imaging features (e.g., cardiac MRI, DXA, digital mammography) and electronic health record (EHR) variables to estimate the mid- and long-term risk of cardiovascular events (CVD) in women aged 40-60. The endpoint is the first occurrence of a fatal or non-fatal CVD event after the imaging test, as documented in the EHR. The models will be compared against standard risk assessment tools (e.g., SCORE2).

    Time frame: Baseline

  4. RO4. Multimodal EHR and ImageBased CVD Prediction Models

    The occurrence of CVD events, which will be classified in fatal (if they are registered as the cause of death) or not fatal (if they are not registered as cause of death). * Fatal CVD events include the following ICD codes registered in the EHR: * I10-16 Hypertensive disease * I20-25 Ischemic heart disease * I46-52 Arrhythmias and heart failure, excluding I51.4 (Myocarditis unspecified) * I60-69 Cerebrovascular diseases * I70-73 Atherosclerosis/AAA * Not fatal CVD events include only the following ICD codes: * I21-I23 Not fatal myocardial infarction * I60-69 Not-fatal stroke

    Time frame: Up to 16 years

  5. RO5. Automatic imaging marker and pattern extraction

    The performance and clinical relevance of AI-based tools for the automatic extraction of cardiovascular imaging biomarkers in women aged 40-60. These tools will be used to segment anatomical regions and calculate quantitative measures from multimodal imaging (e.g., ultrasound, DXA, cardiac CT, cMRI, mammography).

    Time frame: Baseline

  6. RO6. Signal-based CVD prediction models

    Occurrance of CVD events, which include: * The occurrence of Arrhythmia episodes including atrial fibrillation, ventricular tachycardia, and bradyarrhythmias. * The occurrence of Heart failure and structural heart disease, particularly severe left ventricular dysfunction and cardiomyopathy. * The occurrence of Ischemic events such as myocardial infarction (MI), coronary artery disease (CAD), and cerebrovascular accidents (CVA). * Device-related events, including the transition from loop recorders to pacemakers or ICDs due to worsening conditions. Unit of Measure: Recorded episodes (frequency/time) or binary outcome (present/absent).

    Time frame: Up to 16 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for Dec 2027, 21 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
May 31, 2025
StartEst.
Mar 1, 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Apr 30, 2028
Last update
Jan 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06999317
Lead sponsor
Hospital Universitario Virgen Macarena
Collaborators
VISUAL INTERACTION & COMMUNICATION TECHNOLOGIES - VICOMTECH, Clinic for Cardiovascular Diseases Magdalena, Biokeralty Research Institute, Keralty SAS. Colombia, ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON, Fundación Pública Andaluza para la gestión de la Investigación en Sevilla, University of Dublin, Trinity College, TREE Technology S.A., Dublin City University, Tampere University, Ben-Gurion University of the Negev, Biogipuzkoa Health Research Institute, Vilnius University Hospital Santaros Klinikos
Responsible party
Luis Gabriel Luque Romero (Head of Primary Care Clinical Research Unit, Hospital Universitario Virgen Macarena) — Principal investigator
First posted
May 31, 2025
Start date
Mar 1, 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Jan 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion